


# OvRSeq Analysis Report for TCGA-04-1331

2023-11-27

The vulnerability map indicate based on BRCAness probability and CYT to C1QA ratio (C2C) indications with a high vulnerability (score) for response to combination immunotherapy with PARPi and immune checkpoint inhibitors.




## Patient Values

Feature	Value
BRCAness Status	1 (0.818)
Infiltration Status	Desert
Molecular Subtypes	PRO consensus
BRCAness immunotype	other
Vulnerability Score	2.389
Immuno Phenoscore	1
CYT to C1QA Ratio	0.002
Angiogenesis Score	

## Molecular markers and TCGA-OV Reference Values

Marker gene expression levels and respective Q1 and Q3 levels (interquartile range) from the TCGA cohort.



Feature	Patient Value	TCGA IQR
CD274	1.21	1.325 (0.874-1.859)
GZMB	2.149	2.548 (1.625-3.511)
PRF1	0.627	1.731 (1.152-2.505)
C1QA	6.111	7.35 (6.411-8.18)
CD8A	1.097	1.904 (1.168-2.648)
IDO1	4.113	4.161 (2.802-5.446)
FOXP3	1.748	1.938 (1.318-2.521)
TREM2	3.606	4.83 (3.761-5.638)
STAT1	7.266	7.015 (6.207-7.551)
HLA-DRA	5.214	7.262 (6.298-8.001)
CXCL10	4.719	6.379 (5.032-7.539)

